 Home > Active Ingredient News > Antitumor Therapy > Accurately grasping the timing of switching TKI therapy is the key to achieving long-term survival of ALK-positive lung cancer!

Accurately grasping the timing of switching TKI therapy is the key to achieving long-term survival of ALK-positive lung cancer!

 Last Update: 2022-09-08
 Source: Internet
 Author: User

Tags

ilevo seed treatment

patchouli oil side effects

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

*For medical professional reading reference only

To standardize the use of sequential therapy, the timing of switching TKIs is a key point

The significant clinical benefit of the first-line sequential treatment mode of crizotinib has been fully confirmed by clinical studies and real-world experience, successfully setting a new benchmark for 7-year long-term survival for ALK-positive advanced NSCLC, and the continuous development of targeted drugs It is also expected to further prolong survival

Reference: [1].

*This article is only used to provide scientific information to medical professionals and does not represent the views of this platform

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Nedaplatin

CAS No.: 95734-82-0

Industrial Grade

$100/KG EXW

Dideu API Morniflumate CAS 65847-85-0 99.0%

CAS No.: 65847-85-0

Pharmacy Grade

$150-160/KG FOB

Osimertinib Mesylate 99% White Powder CAS 1421373-66-1 EGC-Osimertinib Mesylate Price

CAS No.: 1421373-66-1

Pharmacy Grade

$8-10/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.